Intellectual Property

Category: Intellectual Property, Pharmaceuticals/Biotech/Life Sciences

Spanish Life Sciences Trend Analysis

by C5 Communications - Aug 8 2017

Spain is ranked as the 10th scientific power in the world, and 5th by scientific production in the EU 15. For life sciences companies, Spain offers both Governmental and infrastructure support. The Spanish Government provides low interest credits and incentives for companies during the start-up and growth phase. The region also has a rapidly growing…

Category: Intellectual Property, Pharmaceuticals/Biotech/Life Sciences

Dutch Life Sciences Trend Analysis 2017

by C5 Communications - Jul 25 2017

The Netherlands is a leader in the life sciences and biotech industry, ranked as No.4 worldwide for medical technology patent applications and No. 9 worldwide for biotechnology patent applications. More than 2,500 life sciences, medical technology companies and research organisations call the country home, and the region has attracted major multinational companies, including Johnson &…

Category: Intellectual Property, Pharmaceuticals/Biotech/Life Sciences

Switzerland: Life Sciences 2017 Trend Analysis

by C5 Communications - Jul 10 2017

Switzerland holds only 0.1% of the world’s population, but it remains a leader in wealth, exports and life sciences.  As a smaller country, Switzerland frequently looks beyond its borders, building strong international relationships and focusing heavily on exports.  Currently its largest export sector is chemical, pharmaceutical and biotech, accounting for 41% of total Swiss exports.…

Category: Intellectual Property, Pharmaceuticals/Biotech/Life Sciences

UK Life Sciences Trend Analysis 2017

by C5 Communications - Jun 28 2017

The UK is firmly established as a global centre for life sciences, with a strong history of innovation and entrepreneurship. Across the life science sector, almost half a million jobs are supported, with the activities of these companies directly contributing £14.5bn to the economy, and providing an additional £15.9bn indirectly. Pharmaceuticals dominate the sector, but…

Category: Expert Guest Blog Entries, Intellectual Property, Legal Conferences, Litigation, Pharmaceuticals/Biotech/Life Sciences, Telecoms & Technology

Beatriz San Martin

by C5 Communications - Jan 22 2014

Beatriz is a Partner in the IP & Technology Dispute Resolution Group at Field Fisher Waterhouse LLP.  She has a degree and PhD from the University of Cambridge specialising in genetics, cellular and molecular biology. Beatriz has a broad practice area advising clients in all aspects of intellectual property, with a particular focus on patents,…

Category: Expert Guest Blog Entries, Intellectual Property, Litigation, Pharmaceuticals/Biotech/Life Sciences, Telecoms & Technology

Phil Bilney

by C5 Communications - Jan 22 2014

Phil Bilney is a solicitor in the IP & Technology Dispute Resolution Group at Field Fisher Waterhouse LLP.  Phil advises on a wide range of IP disputes, with a particular emphasis on patent related disputes.  He has acted for a range of clients, and has a keen interest in the Life Sciences sector having studied…

Category: Intellectual Property, Legal Conferences, Litigation, Pharmaceuticals/Biotech/Life Sciences

Competition versus Patents – Anatomy of an underlying policy tension

by C5 Communications - Jan 21 2014

By Bertold Bär-Bouyssière[1] 2013 has seen significant tensions between antitrust enforcement and patents. The various “pay for delay” cases are the most visible development, but there are many others. increasingly, competition authorities challenge the use of patents or virtually ignore them when applying competition law. What is the ideology behind these occurrences? The short article…

Category: Intellectual Property, Legal Conferences, Pharmaceuticals/Biotech/Life Sciences

Patent Settlements as an endangered species

by C5 Communications - Jan 7 2014

  Authors       James R.M. Killick   Partner   White & Case   Practice Experience   James Killick heads the Firm’s Global Pharmaceuticals and Healthcare practice. He is a litigator with a broad range of European law experience, advising clients on pharmaceuticals, competition, international trade (customs, export control, dumping) and State aid. He…

Category: Intellectual Property, Legal Conferences, Litigation, Pharmaceuticals/Biotech/Life Sciences

Pharma and Biotech Patent Litigation

by C5 Communications - Dec 16 2013

The Chinese People’s Court shifts the burden of proof to the defendant in a known-compound preparing process patent infringement case By Dr. Stephen ZOU* Due to lack of discovery procedure, in China, it is very difficult for the patentee to enforce a process patent, especially a process patent for a known product. In Ashland Licensing and…

Category: Intellectual Property, Legal Conferences, Litigation, Pharmaceuticals/Biotech/Life Sciences

Pharma and Biotech Patent Litigation

by C5 Communications - Dec 16 2013

The Chinese Supreme People’s Court expressly opines how to construe a close-ended claim, By Dr. Stephen ZOU* In the [2012] Civil Retrial No. 10, the Chinese Supreme People’s Court (hereinafter “SPC”) delivers its opinion regarding how to construe a close-ended claim. The patent at issue claims a freeze-dried powder injection, consisting of ATP and magnesium chloride…

Category: Intellectual Property, Legal Conferences, Litigation, Pharmaceuticals/Biotech/Life Sciences, Regulatory Compliance and Trade

The current scenario of mailbox patents in Brazil

by C5 Communications - Dec 12 2013

  Overview An Opinion drafted by the Brazilian Patent and Trademark Office (BPTO) legal department regarding the patent term for pharmaceutical products or chemical products for agriculture filed between January 1st, 1995 and May 14th, 1997, the so called “mailbox” patents, was published in the official patent gazette on September 10th, 2013. On September 11th,…

Category: Anti-Corruption / FCPA, Intellectual Property, Legal Conferences, Litigation, Pharmaceuticals/Biotech/Life Sciences, Regulatory Compliance and Trade

Life Sciences – Weekly Industry News

by C5 Communications - Nov 28 2013

(BW) Teva and Mylan Settle Copaxone(R) Patent Litigation in France, the UK and the Netherlands, Posted on The Wall Street Journal JERUSALEM–(BUSINESS WIRE)–November 25, 2013–  Teva Pharmaceutical Industries (NYSE:TEVA) and Mylan Inc. (NASDAQ:MYL) today announce that certain of their affiliates have agreed to settle and dismiss pending patent litigation involving Copaxone(R) (glatiramer acetate) in the United…